Immunoassays are biochemical tests that measure the presence or concentration of a substance, commonly a protein, in a solution using the reaction of an antibody or antibodies to its antigen. These tests are critical in diagnostics, research, and biopharmaceuticals for detecting and monitoring diseases such as cancer, autoimmune disorders, and infectious diseases.

The global immunoassay market was valued at $35 billion in 2023 and is projected to reach $61.6 billion by 2033, growing at a CAGR of 5.8% from 2024 to 2033.

The market's growth is driven by technological advancements in immunoassay platforms, the increasing prevalence of chronic and infectious diseases, and the rising demand for high-throughput and automation solutions in laboratories. Furthermore, the development of novel biomarkers, expansion in biotechnology, and a growing focus on precision medicine contribute to the robust expansion of this market.

Key players like Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Danaher Corporation are pioneering innovations in immunoassay technologies and expanding their portfolios to cater to the increasing demand.

This report provides a comprehensive quantitative analysis of the current market trends and future projections from 2024 to 2033, covering various immunoassay types, end users, and regions.

The report has the following key findings:

• Market Value: The global immunoassay market was valued at $35 billion in 2023 and is projected to reach $61.1 billion by 2033, with a CAGR of 5.8% during the forecast period.

• By Technology: Enzyme-linked immunosorbent assay (ELISA) remains the most dominant segment due to its widespread use in diagnostics and research.

• By Region: North America leads the market, followed by Europe, while Asia-Pacific is expected to grow fastest.

• By Specimen: Oncology, infectious diseases, and cardiology dominate the specimen segments, driven by the rising prevalence of these conditions.

• March 2024: Roche Diagnostics launched a next-generation immunoassay analyzer with enhanced sensitivity and reduced turnaround times, revolutionizing clinical diagnostics.

• January 2024: Abbott Laboratories introduced a new immunoassay panel focused on early detection of cardiovascular diseases, significantly improving diagnostic outcomes for high-risk patients.

• July 2023: Siemens Healthineers received FDA approval for a novel immunoassay targeting Alzheimer's biomarkers, marking a milestone in neurodegenerative disease diagnostics.

• July 2023: Roche Diagnostics India has launched the Elecsys HCV Duo, India's first fully automated immunoassay for simultaneous and independent detection of hepatitis C virus (HCV) antigen and antibody from a single plasma or serum sample.

• November 2022: Bio-Rad Laboratories, Inc. expanded its QC product line with InteliQ and Liquichek compact vials for Abbott Alinity ci-series clinical chemistry and immunoassay instruments.